Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00910650|
Recruitment Status : Completed
First Posted : June 1, 2009
Results First Posted : August 4, 2021
Last Update Posted : December 6, 2021
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans. In this phase 2 study, the experimental products are given initially to a group of 8 people. If safe and found to have significant anti-tumor activity, it will be given to up to 14 other people, for a total of 22 people in this study. Physicians watch subjects carefully for any harmful side effects. Although the experimental regimen has been well tested in laboratory and animal studies, and a similar regimen has been given to a group of patients at the National Cancer Institute in Bethesda, MD, the side effects in people cannot be completely known ahead of time. This protocol is offered only to people whose condition cannot be helped by other known treatments.
The study procedures will start with the collection of white blood cells through apheresis (a procedure in which blood is drawn from a patient and separated into its components, some of which are retained, such as white blood cells, and the remainder returned by transfusion to the patient).
Subjects will be asked to undergo two aphereses, one to make the gene-modified MART-1 TCR CTLs (cytolytic T lymphocyte) and the dendritic cell vaccines, and a second one after the subject receives the gene modified cells to later study them in the blood.
On the day of the first apheresis, subjects will be admitted to the hospital and will receive chemotherapy over the next five days which decreases the risk of rejection of the transferred cells by the subject's immune system and facilitates their expansion and attack of the melanoma lesions. During this time, the gene-modified MART-1 TCR CTLs and the dendritic cells will be manufactured in the laboratory from the apheresis product and will be extensively tested to assure that they express the appropriate TCR and that they do not contain any contaminating bacteria or virus. Then the gene-modified MART-1 TCR CTLs will be given back to the subject through a vein in the arm. It will be followed by vaccination with the dendritic cells under the skin. During the next fourteen days, subjects will also receive interleukin 2 (IL-2), which is a standard treatment for patients with metastatic melanoma. During the next 2 to 3 weeks, subjects will stay in the hospital until the study investigators determine that the subject has fully recovered from all of the procedures, and it is safe for the subject to go home. Chemotherapy frequently causes a decrease in the platelet or red blood cells, and therefore subjects may require platelet and/or red blood cell transfusions.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Melanoma||Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells Drug: non-myeloablative conditioning chemotherapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adoptive Transfer of MART-1 F5 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of MART-126•35-Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Melanoma|
|Actual Study Start Date :||October 13, 2009|
|Actual Primary Completion Date :||May 30, 2019|
|Actual Study Completion Date :||May 30, 2019|
Experimental: F5 TCR transgenic cells
F5 TCR transgenic cell adoptive transfer therapy
Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
Drug: non-myeloablative conditioning chemotherapy
Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
- Response Rate: The Number of Participants Who Completed the Maximum Time Allowed on Study Without Being Affected by Tumor Recurrence or Progression. [ Time Frame: every 90 days for up to 3 years ]
- Overall Survival (OS) [ Time Frame: Baseline from treatment for the life of the participant > 7 years ]Overall survival is measured until the patient passes away
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910650
|United States, California|
|University of California Los Angeles, David Geffen School of Medicine|
|Los Angeles, California, United States, 90095|
|Principal Investigator:||Antoni Ribas, MD||University of California, Los Angeles|
|Principal Investigator:||Bartosz Chmielowski, MD, PhD||University of California, Los Angeles|
|Principal Investigator:||James S Economou, MD, PhD||University of California, Los Angeles|
|Principal Investigator:||John A Glaspy, MD, MPH||University of California, Los Angeles|